RECENT FUNDING
  1. Recent Funding
  2. Companies
  3. IDRx

IDRx

IDRx is a clinical-stage biopharmaceutical company that develops oncology-based precision therapies.

Latest funding

$120M Series B+ ·

Led by Blackstone · Source: fundraisingfox.com

Total raised: $242M across 2 sourced rounds

All 2 rounds ↓

Acquired by GGlaxoSmithKline on .

Website: idrx.com.
LinkedIn: linkedin.com.
Category: Health and bio.
Sectors: Biotechnology, Life Science, Oncology, Product Research.
Stage: Series B+.
Based in: Cambridge, United States.
Founded: 2022.
Total raised: $242M in 2 sourced rounds.
Last round: Aug 8, 2024 · 830 days ago.
Headcount: 11–50 employees.
On Recent Funding since: Oct 1, 2026.

Signals

Website registeredJul 30, 2005 (21 years old)
About IDRx

It designs precision combination therapies, which are medicines with engineered drug combinations. These therapies aim to stop key tumor escape mechanisms and prolong response to therapy for gastrointestinal stromal tumors.

TIMELINE · MONEY RAISED

IDRx | 1567 days on the record

Raised $242M in 2 sourced rounds
$61M$121M$182M$242MAUGMAROCTMAYDECJULFEBSEP$242M$122M Series A · Aug 2, 2022$122M A · AUG '22$120M Series B+ · Aug 8, 2024$120M B+ · AUG '24Acquired by GlaxoSmithKline · Jan 13, 2025ACQUIRED BY GLAXOSMITHKLINE · JAN '25

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

DateRoundAmountLeadSource
Series B+$120MBBlackstonefundraisingfox.com
Series A$122MAAndreessen Horowitzfundraisingfox.com

Timeline

  1. Acquired by GGlaxoSmithKline
  2. Website created

Founders and team

Investors

Companies like IDRx

Other companies backed by Blackstone

Blackstone portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/idrx (get a free API key).

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy